Small molecule · developed by ImmunityBio
5-Fluorouracil is a pyrimidine analog that is studied in non-small cell lung cancer. The only source supplied gives its chemical name, 5-fluoro-2,4(1H,3H)-pyrimidinedione, and does not describe its mechanism of action.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03574649 | Phase 2 | Non Small Cell Lung Cancer | Withdrawn | IBRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non Small Cell Lung Cancer
Updated Oct 11, 2026. Something wrong or missing? Report it on the IBRX page.
See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBRX catalysts and pipeline →